I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| microglial cell | 4 studies | 34% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| microglial cell | 4 studies | 34% ± 10% |
Insufficient scRNA-seq data for expression of APOC2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 85016.72 | 226 / 226 | 88% | 14.34 | 358 / 406 |
| brain | 94% | 687.87 | 2492 / 2642 | 21% | 0.39 | 145 / 705 |
| lung | 93% | 451.62 | 540 / 578 | 1% | 0.01 | 8 / 1155 |
| adrenal gland | 86% | 159.86 | 223 / 258 | 0% | 0.01 | 1 / 230 |
| kidney | 80% | 210.09 | 71 / 89 | 1% | 0.01 | 7 / 901 |
| spleen | 55% | 134.35 | 133 / 241 | 0% | 0 | 0 / 0 |
| skin | 21% | 17.79 | 380 / 1809 | 10% | 0.37 | 49 / 472 |
| intestine | 30% | 60.47 | 292 / 966 | 0% | 0.01 | 2 / 527 |
| prostate | 29% | 26.98 | 70 / 245 | 0% | 0 | 0 / 502 |
| breast | 26% | 33.95 | 119 / 459 | 0% | 0.00 | 2 / 1118 |
| peripheral blood | 23% | 156.29 | 210 / 929 | 0% | 0 | 0 / 0 |
| pancreas | 14% | 27.28 | 47 / 328 | 0% | 0 | 0 / 178 |
| blood vessel | 14% | 42.51 | 186 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 13% | 15.94 | 87 / 653 | 0% | 0 | 0 / 605 |
| bladder | 10% | 8.62 | 2 / 21 | 0% | 0 | 0 / 504 |
| adipose | 9% | 18.66 | 105 / 1204 | 0% | 0 | 0 / 0 |
| esophagus | 5% | 5.09 | 67 / 1445 | 2% | 0.06 | 4 / 183 |
| uterus | 6% | 9.40 | 10 / 170 | 0% | 0.01 | 1 / 459 |
| stomach | 4% | 3.45 | 13 / 359 | 0% | 0.00 | 1 / 286 |
| ovary | 4% | 2.44 | 7 / 180 | 0% | 0 | 0 / 430 |
| heart | 3% | 3.59 | 25 / 861 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.36 | 4 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0045833 | Biological process | negative regulation of lipid metabolic process |
| GO_0070328 | Biological process | triglyceride homeostasis |
| GO_0034382 | Biological process | chylomicron remnant clearance |
| GO_0010898 | Biological process | positive regulation of triglyceride catabolic process |
| GO_0045723 | Biological process | positive regulation of fatty acid biosynthetic process |
| GO_0034372 | Biological process | very-low-density lipoprotein particle remodeling |
| GO_0010916 | Biological process | negative regulation of very-low-density lipoprotein particle clearance |
| GO_0043691 | Biological process | reverse cholesterol transport |
| GO_0060697 | Biological process | positive regulation of phospholipid catabolic process |
| GO_0033700 | Biological process | phospholipid efflux |
| GO_0032375 | Biological process | negative regulation of cholesterol transport |
| GO_0016042 | Biological process | lipid catabolic process |
| GO_0034371 | Biological process | chylomicron remodeling |
| GO_0034384 | Biological process | high-density lipoprotein particle clearance |
| GO_0034370 | Biological process | triglyceride-rich lipoprotein particle remodeling |
| GO_0010902 | Biological process | positive regulation of very-low-density lipoprotein particle remodeling |
| GO_0048261 | Biological process | negative regulation of receptor-mediated endocytosis |
| GO_0051006 | Biological process | positive regulation of lipoprotein lipase activity |
| GO_0010518 | Biological process | positive regulation of phospholipase activity |
| GO_0033344 | Biological process | cholesterol efflux |
| GO_0042632 | Biological process | cholesterol homeostasis |
| GO_0042627 | Cellular component | chylomicron |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0034366 | Cellular component | spherical high-density lipoprotein particle |
| GO_0005769 | Cellular component | early endosome |
| GO_0034362 | Cellular component | low-density lipoprotein particle |
| GO_0034361 | Cellular component | very-low-density lipoprotein particle |
| GO_0034363 | Cellular component | intermediate-density lipoprotein particle |
| GO_0016004 | Molecular function | phospholipase activator activity |
| GO_0140677 | Molecular function | molecular function activator activity |
| GO_0008289 | Molecular function | lipid binding |
| GO_0055102 | Molecular function | lipase inhibitor activity |
| GO_0060230 | Molecular function | lipoprotein lipase activator activity |
| GO_0043274 | Molecular function | phospholipase binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | APOC2 |
| Protein name | Apolipoprotein C-II (Apo-CII) (ApoC-II) (Apolipoprotein C2) Apolipoprotein C2 Apolipoprotein C-II (Apo-CII) (ApoC-II) (Apolipoprotein C2) [Cleaved into: Proapolipoprotein C-II (ProapoC-II)] |
| Synonyms | APC2 |
| Description | FUNCTION: Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. In normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL. . FUNCTION: Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. . FUNCTION: Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. . FUNCTION: Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. . FUNCTION: Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. . |
| Accessions | ENST00000252490.7 ENST00000591597.5 P02655 Q6P163 V9GYJ8 ENST00000592257.5 A0A024R0T9 A0A0S2Z3C2 ENST00000585786.1 V9GZ01 ENST00000590360.2 |
